Wntresearch
Business Services · Sweden · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Järnåkravägen 3, Lund, Skane, 222 25, Sw...Phone Number
+46 406501840Website
www.wntresearch.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Wntresearch
Opsy Holding AB is the result of a reverse acquisition of OPSY AB, now under new management with Arne Thor as CEO. The company has undergone a rebranding from Wntresearch to Opsy Holding AB. It aims to provide innovative solutions in its field, targeting clients interested in advanced research and development. The new board is focused on steering the company towards growth and success in the industry.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Wntresearch your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Wntresearch recently announced quarterly report
Check if Wntresearch has recently received funding, and reach out quickly before it becomes old news!
Wntresearch, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Wntresearch is spiking on competitors!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Wntresearch
Funding: Get notified immidiatlly once Wntresearch has new funding data
Product Launch: Get notified when Wntresearch launches new products
Click to see if Wntresearch had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Wntresearch as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Wntresearch is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Wntresearch is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Wntresearch.
Wntresearch Tech Stack
A closer look at the technologies used by Wntresearch
Most Recent Scoops
Left Company
Executive Move
New Hire
Executive Move
Executive Moves, New Hire
Project
Research & Development
New Hire
Executive Move
Executive Move
Board of Directors
Wntresearch News & Media
WntResearch presents ad hoc observations from the NeoFox study at ESMO GI
WntResearch announces that a poster on the previously communicated positive ad hoc observations from the ongoing clinical phase 2 study NeoFox, will be presented at ESMO Gastrointestinal Cancer Congress (ESMO GI), the leading European congress for gastrointestinal cancer held between June 26-29 in Munich, Germany. The poster presented at ESMO GI details ad hoc observations from 110 patients in the ongoing NeoFox study, indicating that a three-week pre-operative treatment with Foxy-5 rapidly reduWntResearch initiates collaboration with Business Sweden with the goal of establishing commercial partnerships for Foxy-5 in Japan and South Korea
WntResearch announces today that the company has initiated a collaboration project with Business Sweden with the aim of establishing one or more commercial partnerships for the drug candidate Foxy-5 with Japanese and South Korean companies. The collaboration takes place within the framework of Business Sweden's export project, which aims to introduce Swedish innovations to new international markets by promoting partnerships and networking, as well as providing financial support for research projWntResearch continues to the next step in the phase 2 study NeoFox with the highest evaluated dose of Foxy-5
WntResearch announces today that the company, after a very fast patient recruitment, has been able to determine that the highest evaluated dose (8 mg/kg) of the drug candidate Foxy-5 will be used in the next step of the proof of concept study NeoFox. Approximately 80 patients with colon cancer will be treated in the second part of the study and an initial efficacy analysis is planned as early as the end of 2024. Previously reportedWntResearch announces the last day for trading in BTU and the first day for trading in warrants series TO 7 and warrants series TO 8
During the period 15 – 29 January 2024, Wntresearch AB ("WntResearch" or the "Company") carried out a rights issue of units, consisting of shares and warrants series TO 7 and TO 8 (the "Rights Issue"). Through the Rights Issue, WntResearch has received approximately SEK 31.4 million before issue costs and, in the event of full exercise of all warrants issued, WntResearch may receive additional proceeds amounting to approximately SEK 26.9 million before issue costs, based
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Wntresearch
Sign Up For FreeTo access detailed company insights
Opsy Holding AB is the result of a reverse acquisition of OPSY AB, now under new management with Arne Thor as CEO. The company has undergone a rebranding from Wntresearch to Opsy Holding AB. It aims to provide innovative solutions in its field, targeting clients interested in advanced research and development. The new board is focused on steering t... Read More
